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Background: Cancer is one of the leading causes of death worldwide. Natural products have been regarded as
important sources of potential chemotherapeutic agents. In this study, we evaluated the anti-proliferative activity of
Argemone gracilenta’s methanol extract and its fractions. We identified those compounds of the most active
fractions that displayed anti-proliferative activity.
Methods: The anti-proliferative activity on different cancerous cell lines (M12.C3F6, RAW 264.7, HeLa) was evaluated
in vitro using the MTT colorimetric method. Identification of the active compounds present in the fractions with the
highest activity was achieved by nuclear magnetic resonance (NMR) and gas chromatography-mass spectrometry
(GC-MS) analyses.
Results: Both argemonine and berberine alkaloids, isolated from the ethyl acetate fraction, displayed high
anti-proliferative activity with IC50 values of 2.8, 2.5, 12.1, and 2.7, 2.4, 79.5 μg/mL on M12.C3F6, RAW 264.7, and
HeLa cancerous cell lines, respectively. No activity was shown on the normal L-929 cell line. From the hexane
fraction, a mixture of fatty acids and fatty acid esters of 16 or more carbon atoms with anti-proliferative activity
was identified, showing a range of IC50 values of 16.8-24.9, 34.1-35.4, and 67.6-91.8 μg/mL on M12.C3F6, RAW
264.7, and HeLa cancerous cell lines, respectively. On the normal L-929 cell line, this mixture showed a range of
IC50 values of 85.1 to 100 μg/mL.
Conclusion: This is the first study that relates argemonine, berberine, and a mixture of fatty acids and fatty acid
esters with the anti-proliferative activity displayed by Argemone gracilenta.
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Cancer is one of the five leading causes of death, and
by 2015 cancer morbidity is expected to climb to nine
million people worldwide [1,2]. This growing trend indi-
cates the deficiency in the current cancer therapies,
which include surgery, radiotherapy, and chemotherapy
[3,4]. There is a critical need for anti-cancer agents with
higher efficacy, and less side effects that can be acquired
at an affordable cost [2,5,6]. In this regard, plants repre-
sent a viable alternative because they have been valuable* Correspondence: anisolborano@guayacan.uson.mx
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unless otherwise stated.resources for traditional remedies since ancient times and
continue to be the major source and inspiration for the
development of therapeutic agents [7,8]. Some phyto-
chemicals have been studied because of their inherent po-
tential to cure diseases, as demonstrated by ancient
medicinal practices [7,9]. Over 50% of anticancer drugs
approved by the United States Food and Drug Administra-
tion since 1960 have been obtained from natural re-
sources, especially from terrestrial plants [5,7]. Clinically
important anticancer agents, such as paciltaxel, camp-
tothecin, and vinblastine, and many other promising anti-
cancer agents, currently under clinical trials, are also
plant-derived compounds [1,10,11]. Mexico is considered
a major supplier of natural resources. Within its greatentral. This is an Open Access article distributed under the terms of the Creative
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genus, locally known as “cardo or chicalote” [12]. Species
such as Argemone mexicana, Argemone pleiacantha, and
Argemone ochroleuca have shown a variety of medicinal
properties, such as antibiotic, sedative, analgesic, antimal-
arial, anti-inflammatory, and anti-tumor effects [12-16].
Argemone gracilenta, another species of the Argemone
genus, grows in desert terrains mainly in the state of
Arizona, South of the United States, and in the states of
Sonora and Baja California Sur, northern Mexico. Previ-
ous studies have shown that Argemone gracilenta is rela-
tively rich in alkaloids (0.33% of the dried plant), mainly
(-)-argemonine that represents over 90% of the total
plant alkaloids; other alkaloids have also been identified
in smaller proportions such as (-)-mutagine, protopin,
muramine, and (+)-reticuline [17].
Biological studies on Argemone gracilenta are scarce,
and for this reason the aim of this work was to evaluate
the anti-proliferative activity of this plant on different
cancerous cell lines and to identify the responsible com-
pounds for such activity.
Methods
General experimental procedures
Melting points were determined on a Fisher Johns melt-
ing point apparatus. The infrared spectra were measured
on a Bruker Vector 22 spectrometer. GC-MS spectra
were acquired using an Agilent 6890 series GC system
and Agilent 5973 mass selective detector, employing a
fused-silica column, 30 m × 0.32 mm HP-5MS (cross-
linked 5% Ph Me silicone, 0.25 μm film thickness). The
temperature of the column was varied from 40 to 250°C
with a slope of 10°C/min and a stay of 5 min at this
temperature. All NMR spectra were recorded on a Var-
ian Unity 400 spectrometer at 400 MHz for 1H NMR,
and 100 MHz for 13C NMR using DMSO-d6 and CDCl3
as solvents. Open column chromatographies were car-
ried out on silica gel 60 (70–230 and 230–400 mesh
[Merck]). Preparative TLC was performed on precoated
silica gel 60 F254 plates (Merck).
Plant material
Argemone gracilenta was collected in Guaymas, Sonora
(28°05′57′ N, 111°03′23′ W), Northwest of Mexico, in
May 2011. The plant was taxonomically identified (cata-
log No. 08274) by Jesús Sánchez Escalante, taxonomist
at the Herbarium of the Universidad de Sonora.
Extraction and fractionation
The plant was dried at room temperature and homoge-
nized (1400 g) with a Whiley mill (200 mesh). An extract
of the homogenized plant was obtained with methanol
(1:10 w/v; plant/methanol) during 10 days under peri-
odic agitation. The extract was filtered and concentratedto dryness on a rotatory evaporator under reduced pres-
sure at 40°C. The methanol extract (130.9 g) was sus-
pended consecutively in n-hexane, ethyl acetate, and
ethanol (3 × 400 mL for each solvent) with constant agi-
tation for 12 h. The volumes obtained (1200 mL) were
concentrated to dryness under reduced pressure at 40°C
to yield 26 g of n-hexane, 12.5 g of EtOAc, and 29.0 g of
EtOH fractions. The methanol extract and fractions were
stored to -4°C in amber glass vials until use [18].
The EtOAc fraction was further chromatographed on a
silica gel column (120 g) eluting with n-hexane-CH2Cl2
(100:0 to 0:100), then CH2Cl2-MeOH (100:0 to 0:100)
mixtures of increasing polarity to yield 11 fractions.
The FAg-4A fraction (9.7 mg, 0.24%), eluted with
CH2Cl2-MeOH (98:2), was obtained as a yellow-orange oil.
The FAg-5B fraction (450 mg, 11.2%), eluted with
CH2Cl2-MeOH (98:2), was obtained as a colorless oil.
The FAg 7 fraction (20. 5 mg, 0.51%), eluted with
CH2Cl2-MeOH (85:15), was subjected to preparative
TLC (CH2Cl2-MeOH, 8:2) to yield 6.3 mg of argemonine
(Rf = 0.8) and 7.9 mg of berberine (Rf = 0.7).
Argemonine. Mp 122.3-123.4°C (melting point of ref-
erence 147-148°C [19]), 1H NMR (CDCl3, 400 MHz), δ
ppm; 2.52 (d, J = 6.0 Hz, Hα-5 and Hα-11), 2.45 (s, N-
CH3), 4.04 (dd, J = 6.61 Hz, H-6 and H-12) 3.58 (s, 3-
OCH3 and 9-OCH3), 3.66 (2-OCH3 and 8-OCH3), 3.33
(d, J = 5.2 Hz, Hβ-5 and Hβ-11), 6.31 (s, H-1 and H-7),
6.47 (H-4 and H-10). 13C NMR (CDCl3, 100 MHz), δ
ppm; 33.3 (C-5 and C-11), 39.7 (N-CH3), 56.3 (C-6 and
C-12), 55.6 (3-OCH3 and 9-OCH3), 55.8 (2-OCH3 and
8-OCH3), 109.7 (C-4 and C-10), 111.3 (C-1 and C-7),
122.5 (C-4a and C-10a), 127.4 (C-1a and C-7a), 147.9
(C-3 and C-9), 148.4 (C21 and C-8).
Berberine. Mp 144.3-146.1°C (melting point of refer-
ence 146°C [19]) 1H NMR (CD3OD, 400 MHz), δ ppm;
3.26 (t, J = 5.6 Hz, H-5), 4.12 (s, 9-OCH3), 4.35 (s, 10-
OCH3), 4.95 (t, J = 5.6 Hz, H-6), 6.13 (s, 3-OCH2O), 6.89
(s, H-4), 7.45 (s, H-1), 7.95 (d, J = 7.98, H-12), 8.00 (d, J =
7.98, H-11), 8.61 (s, H-13), 9.78 (s, H-8). 13C NMR
(CD3OD, 100 MHz), δ ppm; 28.2 (C-5), 57.1 (C-6), 57.6
(9-OCH3), 62.5 (10-OCH3), 103.6 (2,3-OCH2O), 106.5 (C-1),
109.3 (C-4), 121.5 (C-13), 121.9 (C-4a), 123.3 (C-12a),
124.5 (C-12), 128 (C-11), 131.9 (C-14a), 135.1 (C-8a),
139.6 (C-14), 145.7 (C-9), 146.4 (C-8), 149.9 (C-3), 152
(C-2 and C-10).
GC-MS analysis of fractions Fag-4A and Fag-5B
The content of fatty acids and fatty acid esters in frac-
tions FAg-4A and FAg-5B was analyzed by gas chroma-
tography (Agilent 6890) coupled to a quadrupole mass
detector in electron impact mode at 70 eV (Agilent
5973 N). A solution of 5 mg of each subfraction in 1 mL
of solvent (methanol or dichloromethane) was prepared.
Volatile compounds were separated on an HP 5MS
Table 1 Anti-proliferative activity (IC50 values) of the methanol extract and fractions of Argemone gracilenta on




Methanol Hexane Ethyl acetate Ethanol Residual
M12.C3F6 46.20 ± 8.41ª 20.40 ± 2.30c 32.60 ± 1.10b 21.08 ± 0.84c 40.60 ± 10.08a
RAW 264.7 64.45 ± 8.97ª 36.06 ± 6.55d 41.27 ± 4.27c 55.18 ± 8.80b 64.65 ± 5.36ª
HeLa 78.87 ± 8.52b 70.62 ± 5.80c 126.28 ± 5.73ª > 200* > 200*
L-929 160.60 ± 2.15b 131.30 ± 3.39c 180.61 ± 4.37ª > 200* > 200*
Data are shown as the mean ± SD from three independent repeats after a 48-h exposure to the test extract and fractions. Significant differences (p < 0.05) are
indicated by different letters (a-d). The asterisk (*) represents the maximum concentration tested that did not reach IC50 values.
Table 2 Anti-proliferative activity (IC50 values) of the
most active subfractions from the ethyl acetate fraction




FAg-4A FAg-5B FAg-7A FAg-7B
M12.C3F6 16.81 ± 4.0b 24.9 ± 2.2a 2.8 ± 0.3c 2.4 ± 0.4c
RAW 264.7 34.1 ± 5.8b 35.4 ± 10.14b 2.5 ± 0.5b 2.7 ± 0.1b
HeLa 91.8 ± 7.6a 67.61 ± 5.6c 12.1 ± 1.7d 79.5 ± 11.5b
L-929 151.7 ± 1.5a 85.1 ± 2.3b > 100* > 100*
Data are shown as the mean ± SD from three independent repeats after a 48-h
exposure to the test subfractions. Significant differences (p < 0.05) are indicated
by different letters (a-d). The asterisk (*) represents the maximum concentration
tested that did not reach IC50 values.
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ness). The oven temperature was set at 40°C for 2 min and
then programmed from 40 to 260°C at 10°C/min, and kept
for 20 min at 260°C. Mass detector conditions were as fol-
lows: interphase temperature was 200°C and mass acquisi-
tion ranged from 20 to 550. Temperatures of the injector
and detector were set to 250°C and 280°C, respectively.
The splitless injection mode was performed with 1 μL of
the oily extract. The carrier gas was helium at a flow rate
of 1 mL/min. Volatiles were identified by comparing their
mass spectra with those of the National Institute of Stan-
dards and Technology NIST 1.7 library. Semi-quantitative
data were calculated from the GC peak areas without
using correction factors and were expressed as relative
percentage (peak area %) of the total volatile constituents
identified.
Cell lines and cell culture
The M12.C3F6 (murine B-cell lymphoma) and RAW
264.7 (macrophage, transformed by Abelson murine
leukemia virus) cells lines were kindly provided by Dr.
Emil R. Unanue (Department of Pathology and Immun-
ology, Washington University in St. Louis, MO). Cell
lines NCTC clone L-929 (normal subcutaneous connect-
ive tissue) and HeLa (human cervix carcinoma) were
purchased from the American Type Culture Collection
(ATCC, Rockville, MD). All cell cultures were carried
out in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 5% heat- inactivated fetal calf serum
and grown at 37°C in an atmosphere of 5% CO2.
Cell viability assay
The MTT assay was used to evaluate the anti-
proliferative activity. It is a colorimetric assay based in
the fact that mitochondrial oxidoreductase enzymes are
capable of reducing the tetrazolium dye MTT 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to
its insoluble formazan, which has a purple color. The
cellular oxidoreductase enzymes may, under defined
conditions, reflect the number of viable cells present.
Briefly, cells were seeded in a 96-well plate with DMEM
medium (high glucose, supplemented with 5% FBS) at adensity of 10,000 cells/well. Different concentrations of
methanol extract and fractions were added followed by
48 h incubation. All experiments were conducted in
parallel with controls (0.06%-0.5% DMSO). Ten microli-
ters of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT, 5 mg/mL; Sigma, USA) were
added to each well at the end of the treatment period
and incubated at 37°C for 4 h. Formazan crystals were
dissolved with acidic isopropanol, and the plates were
read in an ELISA plate reader, using a test wavelength
of 570 nm and a reference wavelength of 630 nm. Plates
were normally read within 10 min after adding isopro-
panol. The anti-proliferative activity of extracts was re-
ported as IC50 values (IC50 value was defined as the
concentration of extract that inhibits cell proliferation
by 50%) [20].
Statistical analysis
All data were expressed as mean ± SD. Data were sub-
jected to statistical analysis of variance (ANOVA) by com-
paring means with Tukey test (p <0.05). IBM® SPSS® 20
statistical program was used for all statistical analyses.
Results and discussion
Anti-proliferative activity assays were performed using the
MTTcolorimetric assay on three cancerous cell lines (M12.
C3F6, RAW 264.7, and HeLa) and a normal cell line (L-
929) as control. The concentrations used of the methanol
Figure 1 Anti-proliferative activity of the Fag-7A (argemonine) fraction on cell lines. A) M12.C3F6 and B) HeLa, at a concentration of
50 μg/mL. Observation at 48 h in inverted microscope. Morphological changes: condensed nucleus (CN), apoptotic bodies (AB), autophagic
vacuoles (AV), condensed cytoplasm (CC). All images are magnified at 40×. Images shown are representative of at least four such fields of view
per sample and three independent trials.




time (min) Percentage (%)
FAg-4A
Hexadecanoic acid,
methyl ester 18.62 33.39
Hexadecanoic acid,
ethyl ester 19.28 14.98
7-Octadecenoic acid,
methyl ester 20.34 40.83
Linoleic acid ethyl ester 20.95 10.78
FAg-5B
Hexadecanoic acid,
methyl ester 18.62 1.01
Hexadecanoic acid 19.3 9.05
7-Octadecenoic acid,
methyl ester 20.31 8.39
9,12-Octadecadienoic acid 21.11 81.63
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assay was performed in triplicate.
Table 1 shows the results of the in vitro anti-proliferative
activity assays of the Argemone gracilenta’s methanol ex-
tract and its fractions on different cancerous cell lines. The
results are expressed in IC50 values (mg/mL) ± SD. The
United States National Cancer Institute (US-NCI) estab-
lishes that a crude extract that shows an IC50 value of less
than 100 μg/mL is considered active. When the IC50 value
is lower than 30 μg/mL, the US-NCI considers a crude ex-
tract promising for purification and a biological activity
study [3,21]. In the case of pure compounds, they are
considered active when the IC50 values are lower than
4 μg/mL [22,23].
The methanol extract showed activity on the M12.
C3F6 cell line with an IC50 value of 46.20 ± 8.41 μg/mL;
for RAW 264.7 and HeLa cell lines, the extract showed
activity with IC50 values of 64.45 ± 8.97 and 78.87 ±
8.52 μg/mL, respectively. The methanol extract was not
active on the normal cell line L-929 used as control,
since it showed an IC50 value > 100 μg/mL.
After fractionation of the methanol extract, there was
an increment in the activity of some fractions. The ethyl
acetate fraction had greater activity, with an increase in
the anti-proliferative activity mainly on cell lines RAW
264.7 and M12.C3F6 with IC50 values of 32.60 ± 1.10
and 41.27 ± 4.27 μg/mL respectively, and showing no ac-
tivity on the normal cell line L-929, with an IC50 value >
100 μg/mL.
Chromatographic separation of the ethyl acetate frac-
tion yielded 11 subfractions; of these, fractions Fag-4A,
Fag-5B, and the pure compounds argemonine (7A) and
berberine (7B) showed anti-proliferative activity on M12.
C3F6, RAW 264.7, and HeLa cancer cell lines, and on
the L929 control cell line (Table 2). The alkaloid arge-
monine was the most active, with IC50 values of 2.8 and2.5 μg/mL on M12.C3F6 and RAW 264.7 cell lines, re-
spectively (Table 2). Comparing these results with the
methanol extract activity indicates that the activity in-
creased, since argemonine was 25-times more active
than the methanol extract on the RAW 264.7 cell line.
In the HeLa cell line, argemonine showed activity with
an IC50 value of 12.1 μg/mL, which is 6-times more ac-
tive than the methanol extract. On the normal cell line
L-929, it was not active, indicating that argemonine is
selective for cancer cell lines.
Morphological changes in cells caused by the effect of a
compound or fraction isolated from a plant can provide
information about the cell death mechanism activated in
such cells. Various cell death pathways, including apop-
tosis, autophagy, oncosis, etc., have been proposed. Each
of them is characterized by certain morphological changes
that can be used to distinguish them through observation
Figure 2 Structure of the main component in Fag-7A fraction, argemonine: 1H NMR (13C NMR) data.
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clear and cytoplasm condensation and cellular fragmenta-
tion into membrane-bound fragments (apoptotic bodies).
In oncosis, the cell demonstrates swelling, rapid mem-
brane breakdown, swollen nuclei without DNA fragmen-
tation, and organelle swelling. In autophagy, vacuolization
(autophagic vacuoles), degradation of cytoplasm contents,
and a slight chromatin condensation are observed [24].
The cell lines were observed 48 h after exposure to
argemonine and evidence of two different cell death path-
ways was found. In the M12.C3F6 cell line (Figure 1A), au-
tophagic vacuoles and degradation of cytoplasm contents,
characteristic morphological changes of cell death by au-
tophagy, were observed. In the HeLa cell line (Figure 1B),
condensation of the nucleus and cytoplasm, and apoptotic
body formation, characteristic morphological changes of
cell death by apoptosis, were present.
Structural analysis of the active compounds
The composition of FAg-4A and FAg-5B fractions were
obtained by GC-MS analysis (Table 3). The two fractionsFigure 3 Structure of the main component in Fag-7B fraction, berberare composed of fatty acids of 16 or more carbon atoms.
The FAg-4A fraction is a mixture of: 7-octadecanoic acid,
methyl ester (40.83%), hexadecanoic acid, methyl ester
(33.39%), hexadecanoic acid, ethyl ester (14.98%), and
linoleic acid, ethyl ester (10.78%). The FAg-5B fraction
consists of: 9,12-octadecadienoic acid (81.63%), hexadeca-
noic acid (9.05%), 7-octadecenoic acid, methyl ester
(8.39%), and hexadecanoic acid, methyl ester (1.01%).
The compounds argemonine (7A [25] and berberine
(7B [26]) were identified by comparing their spectro-
scopic data with those previously described in the litera-
ture (Figures 2 and 3). The purity of isolated compounds
was determined to be above 95%, based on their 1H-
NMR spectra.
Argemonine is a natural alkaloid from the isoquinoline
group, which has been isolated from plants and seeds of
several species, including some plants of the genus Arge-
mone, such as A. gracilenta, A. platyceras, A. sanguinea,
among others. In addition, it has been found also in spe-
cies of Buxifolia berberis, Thalictrum revolutum, and
T. strictum. The most popular use of argemonine is toine: 1H NMR (13C NMR) data.
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and ricin, because of its antibacterial, fungicidal, and in-
secticidal properties [27]. Biological studies of argemo-
nine are scarce, and its biological activities have not
been determined yet.
Previous studies have shown that other types of isoqui-
noline alkaloids, such as sanguinarine and chelerythrine,
isolated also from species of the Argemone genus, showed
anti-proliferative activity on several cancer cell lines such
as HeLa, MCF-7, A-549, and PC-3 [28]. It has been
pointed out that sanguinarine induces cell cycle arrest in
different phases and apoptosis in a variety of cancer cells
[29], besides possessing a wide spectrum of biological
activities, such as antimicrobial, antifungal, and anti-
inflammatory effects.
Studies on berberine have shown its ability to inhibit
the growth of various human cancer cell lines. These
studies have proven that berberine suppresses cancer cell
proliferation by regulating the cell cycle [3,30-32]. In
2011, it was reported that berberine induces cell death
by autophagy in hepatocellular carcinoma cell lines
HepG2 and MHCC97. Berberine exerts an inhibitory ef-
fect on invasion, migration, metastasis, and angiogenesis
of cancer cells [33,34]. These results illustrate the poten-
tial application of berberine in cancer therapy [3].
Anti-proliferative activity studies have shown that cer-
tain fatty acid compounds inhibit the growth of cancer
cells. Girao evaluated the effect of 18-carbon fatty acids
on the SP210 cell line (mouse myeloma) growth, demon-
strating that unsaturated 18 carbon fatty acids exert anti-
proliferative activity on that cell line, whereas saturated
fatty acids (C18.0, stearic acid) show no cell inhibition ac-
tivity [35]. However, other studies have demonstrated that
some fatty acids stimulate the growth of cancer cells. For
example, arachidonic acid (C-20: 4) stimulates the growth
of human prostate cancer cell line, PC-3, by 122%, but
these studies also found that fatty acids, such as omega-3
eicosapentaenoic acid, exert an inhibitory effect on the
growth of PC-3 cells [36].
Studies of biological activities and the importance of
fatty acids extracted from the Argemone genus are scarce.
For this reason, the results regarding the anti-
proliferative activity of fatty acids, FAG-4A and FAG-5B
fractions, could be the starting point for their further
study as potential inhibitors of a wide range of human
cancer cells, hence, pointing out their relevance in the
battle against cancer.
Conclusions
This study presents the first analysis of the anti-
proliferative activity of Argemone gracilenta on cancerous
cell lines and provides support for the traditional use of this
plant against multiple diseases, as well as of other species of
the Argemone genus. In addition, two alkaloids, berberineand argemonine, with important anti-poliferative activity
were isolated. We present the first analysis of the argemo-
nine alkaloid as an anti-proliferative compound, showing
promising results for future studies as a potential anticancer
drug. Fatty acids and fatty acids esters of 16 or more carbon
atoms with anti-proliferative activity were also identified.
This is also the first time that the anti-proliferative activity
displayed by plants of the Argemone genus is associated to
this type of compounds.
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